EP08.02-136. Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Back to course
Pdf Summary
Asset Subtitle
Juan Shen
Meta Tag
Speaker Juan Shen
Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
Keywords
anlotinib
docetaxel
non-small cell lung cancer
NSCLC
platinum-based chemotherapy
objective response rate
progression-free survival
overall survival
adverse events
treatment option
Powered By